» Articles » PMID: 16042078

G1 Phase Arrest of the Cell Cycle by a Ginseng Metabolite, Compound K, in U937 Human Monocytic Leukamia Cells

Overview
Journal Arch Pharm Res
Specialty Pharmacology
Date 2005 Jul 27
PMID 16042078
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We recently reported that the ginseng saponin metabolite, compound K (20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol, IH901), inhibits the growth of U937 cells through caspase-dependent apoptosis pathway. In this study, we further characterized the effects of compound K on U937 cells and found that, in addition to apoptosis, compound K induced the arrest of the G1 phase. The compound K treated U937 cells showed increased p21 expression; an inhibitory protein of cyclin-cdk complex. The up-regulation of p21 was followed by the inactivation of cyclin D and the cdk4 protein, which act at the early G1 phase, and cyclin E, which acts at the late G1 phase. Furthermore, compound K induced the activation of JNK and the transcription factor AP-1, which is a downstream target of JNK. These findings suggest that the up-regulation of p21 and activation of JNK in the compound K treated cells contribute to the arrest of the G1 phase.

Citing Articles

Anti-leukemia effects of ginsenoside monomer: A narrative review of pharmacodynamics study.

Alavi Dana S, Meghdadi M, Kakhki S, Khademi R Curr Ther Res Clin Exp. 2024; 100:100739.

PMID: 38706463 PMC: 11066596. DOI: 10.1016/j.curtheres.2024.100739.


Functional Mechanism of Ginsenoside Compound K on Tumor Growth and Metastasis.

Liu J, Wang Y, Yu Z, Lv G, Huang X, Lin H Integr Cancer Ther. 2022; 21:15347354221101203.

PMID: 35615883 PMC: 9152193. DOI: 10.1177/15347354221101203.


A narrative review of the pharmacology of ginsenoside compound K.

Liu T, Zhu L, Wang L Ann Transl Med. 2022; 10(4):234.

PMID: 35280413 PMC: 8908159. DOI: 10.21037/atm-22-501.


Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Wang H, Zheng Y, Sun Q, Zhang Z, Zhao M, Peng C J Nanobiotechnology. 2021; 19(1):322.

PMID: 34654430 PMC: 8518152. DOI: 10.1186/s12951-021-01062-5.


Pharmacological properties of ginsenosides in inflammation-derived cancers.

Luong Huynh D, Nguyen N, Nguyen C Mol Cell Biochem. 2021; 476(9):3329-3340.

PMID: 33900512 DOI: 10.1007/s11010-021-04162-w.